Company intelligence / Profile preview

CryoTherapeutics

Liège, Liège Province, Belgiumcryotherapeutics.com ↗

Ownership: Private
Employees: ~19
Development stage: Phase 1

Overview

The company’s CTS system has entered first-in-human clinical trials to demonstrate safety and efficacy for the stabilization of high-risk coronary plaques. The technology aims to prevent heart attacks by delivering targeted cryotherapy to vulnerable arterial plaques. Additional product development and advanced clinical studies are ongoing with recent funding supporting these efforts.

Therapeutic areas: Cardiovascular
Modalities: DeviceNon-pharmacological therapy (cryotherapy)
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

CTS system

Phase 1

Indications: Coronary artery disease, Heart attack prevention

Beyond the preview

Go deeper on CryoTherapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CryoTherapeutics.

Explore the full profile